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the possibility to use β− decaying isotopes for radioguided surgery (RGS) has been recently proposed, 
and first promising tests on ex-vivo samples of Meningioma and intestinal neuroendocrine tumor 
(net) have been published. this paper reports a study of the uptake of 68Ga-DOTATOC in pancreatic 
nets (pnets) in order to assess the feasibility of a new RGS approach using 90Y-DOTATOC. Tumor 
and healthy pancreas uptakes were estimated from 68Ga-DOTATOC PET/CT scans of 30 patients with 
pNETs. From the obtained SUVs (Standardised Uptake Value) and TNRs (Tumor Non tumor Ratio), an 
analysis algorithm relying on a Monte carlo simulation of the detector has been applied to evaluate the 
performances of the proposed technique. Almost all considered patients resulted to be compatible with 
the application of β−-RGS assuming to administer 1.5 MBq/kg of activity of 90Y-DOTATOC 24 h before 
surgery, and a sampling time of few seconds. In just 2 cases the technique would have required a mildly 
increased amount of activity or of sampling time. Despite a high physiological uptake of 68Ga-DOTATOC 
in the healthy pancreas, the proposed RGS technique promises to be effective. This approach allows 
RGS to find application also in pancreatic diseases, where traditional techniques are not viable.
Radio-Guided Surgery (RGS) is a procedure aimed at helping the surgeon to completely and precisely resect a 
tumour. It requires to administer a radio-labeled pharmaceutical, with a specificity to the tumor, to the patient 
before the surgery. Such a radio-pharmaceutical will be detected during the surgery with an handheld detector, 
hereinafter named probe, designed to reveal emitted radiation and, thus, allowing to identify the tumoral area, 
and its borders in particular.
Established methods use nowadays a combination of a γ-emitting radio-pharmaceutical with a 
γ-radiation-detecting probe1,2. The most common isotope is 99mTc, that emits 144 keV photons with a τ = 8.7 h.
However, the use of γ rays constitutes itself a limitation to the applicability and efficacy of the technique. In fact, 
about 1/3 of such photons traverses more than 8 cm in human tissue, implying that the uptake of the compound 
in healthy tissues nearby lesions of interest constitutes a non-negligible background. As a result, γ-RGS is today 
particularly used in those contexts in which the target is located in low uptake regions (e.g. sentinel lymph node).
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A recent prospective study3 has evaluated the possibility of performing γ-RGS in abdominal Neuroendocrine 
Tumors by using 68Ga-DOTATATE as radio-pharmaceutical, i.e. a β+ emitter. Despite overall positive conclu-
sions, the authors highlight that out of the 25% (33/133) of false positive cases, the majority came from pan-
creas, liver and gastro-intestinal tract, i.e. organs characterised by an elevated level of physiological uptake of 
radio-pharmaceutical, or close to organs with a high normal uptake3.
In the view of overcoming these limitations, the use of pure β−-emitting rather than γ-emitting 
radio-pharmaceuticals can be considered. Indeed, electrons emitted in β− decays have a mean free path of few 
millimetres in human tissues. Moreover, as the bremsstrahlung emission has a probability of 0.1% at these energies 
energies, the γ contamination can be considered negligible4.
All in all, the use of a radiation with such a small penetration would allow a higher spatial sensitivity and, 
hence, a clearer delineation of margins of the pathologic tissue with respect to γ emission5. In fact, when dealing 
with electrons, due to pure geometrical reasons, it is just the detector transverse size that determines its spatial 
resolution, i.e. the capacity to discriminate two adjacent sources, or to identify the tumor margin. In particular, 
the FWHM (Full Width at Half Maximum) of the scan profile is expected to be very close to the size of the source 
along the explored projection. Furthermore, the dose to the medical personnel becomes negligible too.
As a matter of fact, the idea of using β− emitting isotopes was at the base of the very first inception of the Radio 
Guided Surgery technique itself6, that however eventually did not succeed into clinical practice due to factual 
limitations at the time in both the radio-pharmaceutical handling and the detector technology. In this context, we 
recently suggested the possibility of a new approach to β−-RGS7–9, starting with the development of a dedicated 
detector. Such detector features high sensitivity to β particles and substantial transparency to γ radiation, that 
constitutes a background in this context, together with the expected exquisite spatial resolution10.
This proposed novel technique of RGS proved not only to be theoretically possible11,12, but also its actual 
feasibility was demonstrated with ex-vivo tests on meningioma13,14, as well as gastro-entero-pancreatic 
Neuroendocrine Tumors (GEP-NET)15,16 samples, marked with 90Y-DOTATOC (pure β− decay with an endpoint 
of 2.2 MeV and half-life τ1∕2 = 64 h).
In particular, the remarkable efficacy showed by β-RGS in GEP-NET ex-vivo tests, whose samples included an 
abundant tract of healthy bowel among which tumors had to be discriminated, enforces the expected adeptness 
of such a technique to locate lesions in a high background situation.
An excellent application case in this view can be represented by pNETs. These are in fact mildly common 
lesions, having a prevalence of 10%17, in which surgical excision is the gold standard treatment, and where the 
possibility to minimise the asportation of healthy pancreas could be of remarkable importance for the patient’s 
outcome. More specifically, pNETs enucleation implies a significantly minor invasiveness as compared to formal 
pancreatectomy, leading to a relevant tissue sparing and less incidence of long-term functional consequences (i.e. 
post-operative diabetes, exocrine insufficiency)18. Moreover, the pancreas thickness is few centimeters, compat-
ible with the use of beta radiation, that could be otherwise obscured if emitted from tumors at greater depths. 
Lastly, as already discussed, this kind of tumor expresses receptors for somatostatine, thus allowing the use of 
90Y-DOTATOC, as in previous aforementioned studies.
Therefore, the aim of this study is to evaluate the possibility to apply β-RGS to pancreatic NETs, using 
90Y-DOTATOC as radio-pharmaceutical.
This technique would in fact improve the intra-operative localization and detection of pNETs, particularly 
difficult especially in case of small tumors19. For instance, this precise tumor localization would be of outmost 
importance to drive the resection, leading to a potential reduction of the current incidence of margin positivity 
after enucleation (R1 margins), reported in almost the 37% of pNETs located in the pancreatic head20.
To such a purpose, a retrospective study on PET images of patients affected by this pathology after administra-
tion of 68Ga-DOTATOC has been performed at Fondazione Policlinico Gemelli, Rome. Following the procedure 
reported in ref. 11,21, we used the measured uptake in tumor and nearby healthy tissues to study the sensitivity of a 
β− probe to the signals of interest, thus evaluating the feasibility of the application of RGS in this case.
Methods
patients population. Thirty patients who had a 68Ga-DOTATOC PET/CT between March 2015 and 
February 2017 and showing a pancreatic uptake likely to be a pNET were retrospectively identified. PET/CT scans 
were performed at the institute of Nuclear Medicine of Fondazione Policlinico Universitario A. Gemelli IRCCS 
in Rome. The Review Board of the clinical institute involved, namely: Comitato Etico Fondazione Policlinico 
Universitario “Agostino Gemelli” - Università Cattolica del Sacro Cuore - Rome, approved this study and all patients 
signed a written informed consent form.
imaging protocols and interpretation. 68Ga-DOTATOC PET/CT. The administered activity of 
68Ga-DOTATOC was 1.5–3 MBq/kg (100–200 MBq), and imaging was acquired between 60 ±  10 min post 
intravenous injection. PET images were acquired for 2–2.5 min per bed position. The whole-body (from head to 
middle of the upper leg) PET/CT was performed on a hybrid scanner (Gemini GXL; Philips Medical Systems, 
Cleveland, Ohio and Biograph mCT, Siemens, Germany). A low-dose CT scan was first performed and then 
PET images of the same field of view were obtained. PET images were reconstructed using an iterative protocol 
and displayed on a dedicated workstation of transaxial, coronal and sagittal planes for anatomical reference and 
attenuation correction purposes22,23.
A line-of-response row-action maximum-likelihood algorithm (3 iterations and 33 subsets, voxel 
size of 4  ×  4 ×  4 mm, no additional gaussian smoothing) or a 3-dimensional (3D) ordered-subsets 
expectation-maximization algorithm with resolution modelling (2 iterations and 21 subsets, voxel size of 
3.2 × 3.2 × 5 mm, additional gaussian smoothing of 2 mm in full width at half maximum) were used for the 
Gemini or Biograph, respectively.
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Image interpretation. Two experienced nuclear medicine physicians interpreted visually PET/CT scans, ana-
lyzed and reviewed the datasets.
Estimate of the DOTATOC uptake. In order to estimate the possibility to apply this technique, the SUV 
(Standardized Uptake Value) and TNR (Tumor Non tumor Ratio) of DOTATOC in pNETs are needed. This is 
possible exploiting PET exams performed with 68Ga-DOTATOC.
The SUV is a semi-quantitative measurement of the amount of radio-pharmaceutical uptake in a given region 
of interest, normalized to the administered activity and to body mass of the single patient. It is defined as: 
 
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in which μ is the mean value of PET activity of the considered area, Aadm is the amount of activity administered, 
W is the patient mass, ΔtPET is the time between the radio-pharmaceutical administration and the PET scan, and 
TGa
1/2 is finally the 68Ga half-life. The Tumor Non tumor Ratio (TNR) is the ratio between the SUVs of the tumor 
and of the background healthy tissue.
Being the application case of this study the intraoperative discrimination of tumor margins and/or remnants 
after the bulk excision, we decided to choose as “tumor” the marginal proximity of the lesion, and as reference 
“healthy tissue” the adjacent area, as depicted in Fig. 1. This is in fact what the surgeon should be able to discrim-
inate from the lesion in a hypothetical application case.
In order to obtain these uptake values, we examined 68Ga-DOTATOC PET scans of the patients in the cohort. 
The “3d-isocontour” tool was used to define ROIs (Regions Of Interest) throughout different slices in which to 
compute the mean uptake, thus forming VOIs (Volumes Of Interest). The threshold value for this ROI selecting 
tool was set to 50% of the maximum value, and the VOIs were chosen to have approximately a volume of 100 mm3 
for homogeneity of comparison.
For each VOI, the mean SUV (SUV), the SUV rms (ΔSUV) and the VOI volume (V) were measured. The error 
on the mean SUV value was then calculated as: 
σ =
Δ
N
,
(2)SUV
SUV
 where N is the number of voxels included in the VOI.
Figure 1. Example of ROI identification in the tumor (right ROI) and in the nearby healthy pancreas (left ROI).
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the β probe. A fundamental element in the development of the β−-RGS technique is the detector to be used 
to reveal electrons. As detailed in previous studies4,11,12,24, we developed a β probe, that exploits the low penetra-
tion power of β particles by diminishing the thickness of the lateral shielding, resulting in a handy and light tool, 
when compared to commercial γ probes. The active element of the detector is made of p-terphenyl, an organic 
scintillator characterised by high light yield and low density24, that makes it an ideal choice to reach good sensi-
tivity to β particles, while remaining substantially transparent to photons.
In particular, the probe prototype that has been tested on β− radiation in a clinical trial with meningioma 
ex-vivo samples, and which is used in this study, is based on a sensitive cylinder of p-terphenyl with a radius of 
2.55 mm and a 3 mm depth. To maximise the accuracy on the direction of the incoming radiation, this sensitive 
region is surrounded by a ring of 3 mm of polyvinylchloride. The scintillation light is transported then read by a 
Silicon Photo Multiplier sensor (SiPm, SenSL series C, mod. 10035), controlled and readout using ArduSiPM25.
It has to be mentioned that in the time elapsed since the meningioma campaign, several advances have been 
made regarding the detector, which has gained in sensitivity. However, for the sake of comparing these studies 
with the previously published ones, in this paper we use as reference the performances of the previous model of 
detector, as a conservative approach.
calculation of expected rates. Once obtained the uptake values from the images, it is necessary to quan-
tify the performances of the probe in the real application scenario. The procedure is detailed in26, and essentially 
relies on a Monte Carlo simulation where the probe is exposed first to a small tumoral remnant encapsulated in 
a healthy tissue cylinder and then to an area of healthy tissue as well. Dimensions have been chosen to be 6 mm 
diameter - 7 mm height for the tumor remnant, thus mimicking a typical volume of a residual to be looked for 
during RGS, and 2 cm diameter - 1 cm height for healthy tissue. In fact, since 90Y electrons penetrate only few 
mm in human tissue, the “field of view” of the probe is limited to particles that originated from few mm in front 
of the active element, and extends transversely according to the horizontal dimension of the scintillator itself (in 
this case 2.55 mm radius). Therefore, further enlarging this “healthy tissue” volume in the Monte Carlo would not 
give additional signal to the probe, since no more particles able to reach the detector are created when generating 
at higher distances from it, but would only have impact on the computational time.
All in all, the mentioned simulation algorithm allows to obtain, from SUV and TNR of the considered tumor, 
the Rates in cps we expect to count on the lesion (RT) and on the nearby healthy tissue (RH) in a real application 
case. Evidently, the amount of injected activity is needed to perform this prediction, as well as the time interval 
between the injection and the performing procedure. These are indeed necessary parameters to predict the spe-
cific activity in the considered areas at the time when RGS is performed. In this study we assumed to inject 1.5 
MBq/kg of 90Y-DOTATOC, which has been evaluated14 as the reasonable minimal value of activity to have good 
discrimination in the case of meningiomas, therefore using a reference total activity (for a 70 kg patient) of 105 
MBq.
Moreover, the long enough physical decay time of 90Y (τ = 92 h) does not put particular operational con-
straints on the time interval between the injection and the procedure. We have demonstrated12 that the 
DOTATOC TNR in NET reaches a maximum at about 24 h post injection, due to the simultaneous action of 
receptor mediated accumulation and healthy organs’ wash out. It is thus possible to conceive an application pro-
tocol in which the patient is injected the day before surgery, thus maximising the efficacy of the technique, hence 
allowing in turn to diminish the activity to be injected.
From the so estimated RT and RH, it is possible to compute the minimum sampling time (ΔTmin) the detector 
needs to be on the area to be able to distinguish with sufficient accuracy tumor from healthy tissue.
To this aim, we applied in this study the same approach described in ref. 7,21, that is based on the computation 
of the rate of false positive (FP) and false negative (FN) signals. For a given value of the probe sampling time 
(tprobe), the number of signal counts coming from the tumour and the background is distributed according to a 
Poisson distribution with mean μT = RT × tprobe and μH = RH × tprobe respectively. Given the minimum number 
of signal counts (μth) needed to identify as positive a spot, FP is evaluated as the fraction of times the background 
would give a positive signal: 
∑= − μ μ=
−
FP P N1 ( ), (3)N 0
1th
H
 where Pμ(N) is the Poisson probability of having N if the mean is μ. In the same way, FN is the fraction of times a 
tumour residual would not yield an above threshold signal: 
∑= .μ μ=
−
FN P N( ) (4)N 0
1th
T
 Intuitively, for a fixed tprobe, rising the μth value would increase the number of healthy zones that are defined as 
“not tumor”, thus diminishing the FN rate. On the other hand, however, it would also rise the number of possible 
tumors that are flagged as “non tumor”, thus increasing the FP rate. The same reasoning stands for the case in 
which μth is fixed and tprobe is varied. To identify the minimum probing time, FN and FP are evaluated in a grid of 
tprobe and μth and the smallest value of tprobe for which FN < 5% and FP ≈ 1% is determined.
Roc analysis. The described procedure allows to estimate the optimal probing time needed on each lesion. 
However, in the real application case, i.e. during the RGS procedure, clinical experience suggests that the time the 
surgeon will spend on each analysed area will be almost constant, and certainly can not depend on the unknown 
real activity of the lesion. First ex-vivo tests15,16 suggest that, independently from the sample uptake, the surgeon 
typically tends to stay on each spot at least ≈3s before being confident enough to determine if it is healthy or not.
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Therefore, a sensitivity analysis has been performed to evaluate the discriminating power of the proposed 
technique, having assumed a fixed probing time of tprobe = 3s, and varying the threshold value (th) in terms of total 
number of counts obtained in this time interval. For each given threshold value, “sensitivity” and “specificity” 
were evaluated and plotted in a ROC curve, the area of which can be used to evaluate the discriminating power 
of the technique.
ethical approval. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
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Figure 2. Distribution of tumor SUVs (top), healthy pancreas SUVs (middle) and TNRs (bottom) for all the 30 
patients.
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Results
Uptake and tnRs. The described analysis procedure has been applied to all the 30 patients to obtain their 
respective SUVs and TNRs. Median SUV was 12.4 (InterQuartile Range 5.5–23.2) for tumors and 2.4 (IQR 1.9–
2.9) for healthy pancreas, with a median TNR of 4.9 (IQR 2.2–12.2). Figure 2 shows SUVs (for both healthy 
pancreas and tumors) and TNRs histograms, while in Fig. 3 the scatter plot of tumor SUV versus TNR is shown.
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Figure 3. Scatter plot showing tumor SUV as a function of TNR for all the 30 patients. Errors shown in the bars 
are obtained as described in the text.
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Figure 4. ROC curve for patient n. 1 (top), and distribution of Area Under Curve of ROCs of all the considered 
patients (bottom). The AUC for the shown case is 0.9999575. The probing time has been fixed to tprobe = 3 s.
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Sensitivity analysis.   Figure 4 (top) shows the ROC curve for patient n. 1, obtained as described before in 
the text. Furthermore, Fig. 4 (bottom) shows the distribution of the Area Under Curve for all the considered 30 
patients.
expected performances of RGS with β decays. Results for SUVs and TNRs shown in Figs. 2 and 3 have 
been used, following the procedure described in the previous paragraph, to obtain the counting rates we expect 
in a real application scenario. The results are shown in Fig. 5, where points are classified according to the ROC 
sensitivity test (“Good” if AUC > 0.95, “Bad” otherwise). In the plot, the bisector represents the “worst case”, in 
which tumor and healthy tissue give the same signal. Median probing time (tprobe) was 0.4 s (IQR 0.1–1.7 s).
  Figure 6 shows the detecting times needed to discriminate the tumor from the surrounding healthy tissue, 
obtained as described earlier in the text, while in Fig. 7 the correlation between the ROC-AUC and this detecting 
time is reported.
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Figure 5. Counting rates expected on lesions (Signal) versus the ones expected on healthy tissue. The dashed 
line is the bisector, representing the case in which the probe gives the exact same count over signal than over 
healthy tissue, having thus no sensitivity at all. Points are classified (“Good” or “Bad”) according to the ROC 
sensitivity test described in the text, having fixed a probing time of 3 s and requiring AUC > 0.95. The rates 
correspond to the application case described in the text (injection of 105 MBq of 90Y-DOTATOC 24 h before the 
surgery).
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Figure 6. Distribution of time (tprobe) needed to discriminate with sufficient accuracy the tumor. The statistical 
criterion used and the considered real case scenario are described in the text.
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Discussion
The goal of this study was to evaluate the possibility to apply an innovative β−-RGS technique to pancreatic 
Neuroendocrine Tumors with 90Y-DOTATOC, using a detector that has been recently developed and tested on 
Meningioma and bowel NET ex-vivo samples13–16.
This technique, with respect to enstablished γ-RGS, would allow a clearer delineation of margins of the patho-
logic tissue together with a substantial reduction of the dose given to the medical staff.
As expected, tumor SUVs and TNRs are found to vary significantly among patients, ranging from less than 2 
in the lowest cases up to more than 100 for the highest one.
On the other hand, the SUV of healthy pancreas has been found to be more consistent among patients, show-
ing smaller variations. It has however to be stressed that the average value of background SUV (median 2.4) has 
been found to be significantly higher than in previous studies dedicated to assessing the feasibility of the proposed 
β-RGS technique in other application cases (of the order of 0.2 for both brain tumors11,12 and prostate cancer21).
This was indeed an expected finding, since healthy pancreas is known for its elevated physiological uptake, 
that has hindered so far any application of traditional Radio Guided Surgery, i.e. exploiting γ decays, notwith-
standing the availability of possible radio-pharmaceuticals like 177Lu-DOTATATE.
Nevertheless, the very good TNR showed by the vast majority of cases, together with the high sensitivity of 
the foreseen detector, that exploits the locality of beta particle emission, allows to perform the proposed tech-
nique with very high efficacy, as highlighted by both the ROC sensitivity test and the time needed to exploit the 
procedure.
In fact, Fig. 6 suggests that a probing time of few seconds is enough to identify all lesions. In our experience 
with ex-vivo tests performed so far, we found out that, independently from the actual probe signal, the operator 
tends to remain on each spot at least  ~ 3–5s, before being confident enough in his/her measurement. It has thus 
to be noted that only in 5 out of 30 cases the sampling time would slightly exceed this 3 s “reaction time”, while 
more than 93% of cases (28/30) would have been detected within 5 s.
Indeed, only 2 cases presented such a low TNR that would imply a needed probing time of about 10 s, which is 
probably an amount of time not compatible with surgical practice. These cases in fact correspond to points near 
the bisector in Fig. 5, representing occurencies in which tumor and healthy tissue uptake were almost similar. 
In this context, it has however to be noted that the application protocol of β-RGS is based on a preliminary PET 
study with 68Ga-DOTATOC, to be performed few weeks before surgery. This exams would be exactly dedicated 
to assess whether the considered lesion shows a TNR sufficient to make the patient an eligible candidate for such 
a technique, or whether an excessive amount of time or injected activity would be needed, thus making this tech-
nique not a viable approach.
Regarding radio protection issues, the use of β− radiation implies, with respect to γ-RGS, a much reduced 
exposure for the medical personnel, that has in fact found to be negligible in the first ex-vivo trials13. On the other 
hand, as far as the patient is concerned, OLINDA calculations suggest that an effective dose of about 25 mSv is 
expected in the considered scenario if the patient is catheterized after the injection, which is easily the case given 
the surgical intervention.
conclusion
In this work we studied the applicability of an innovative β−-RGS technique to pNETs with 90Y-DOTATOC, 
evaluating its uptake with a retrospective study on 68Ga-DOTATOC PET images of 30 patients at Fondazione 
Policlinico Universitario A. Gemelli IRCCS in Rome. The technique has been demonstrated to be feasible by 
injecting the patient with 1.5 MBq/kg of 90Y-DOTATOC 24 h before surgery, with a sampling time for each spot 
of the order of few seconds.
Indeed, despite the expected variability among patients, only in two cases the technique to be effective would 
have required either a mildly increase in the amount of administered activity or a longer sampling time. For all 
the other cases, we found that the patients’ SUV and TNR are compatible with the application of the proposed 
technique.
Figure 7. Area Under Curve of ROCs as a function of the probing needed time tprobe calculated for each of the 
30 patients. Points are classified (“Good” or “Bad”) according to the ROC sensitivity test described in the text, 
having fixed a probing time of 3s and requiring AUC > 0.95.
9Scientific RepoRtS |         (2020) 10:4015  | https://doi.org/10.1038/s41598-020-61075-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
In any case, in the application protocol we propose, we foresee a preliminary PET scan with 68Ga-DOTATOC 
to verify in advance that the technique could be effectively applied to the patient. This would allow also to tailor 
the injected activity accordingly to the individual uptake as discussed in a previous publication14.
To verify the expected performances of the technique, ex-vivo tests on excised pNETs specimens are needed 
and foreseen for the next future. At the same time, we are working on improving the detector to lower signifi-
cantly the minimum detectable energy of the electrons27,28. Such an improvement would in fact lower either the 
probing time, or the administered activity.
Data availability
The data that support the findings of this study are available from the corresponding author on reasonable request.
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